ImpediMed

ImpediMed Current Assets

The Current Assets of ImpediMed (IPD.AX) as of Sep 27, 2026 is 18.85 M AUD. In the previous year, Current Assets was 28.20 M AUD — a change of -33.15% (lower).

Current Assets

18.85 MAUD

YoY

-33.15%

Last updated:

Current Assets of ImpediMed is 2026 18.85 M AUD. Current Assets of ImpediMed was 2025 28.20 M AUD. It decreases by -33.15% lower compared to the previous year.

The ImpediMed Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2019
19.71 M AUD
Jan 1, 2020
28.31 M AUD
Jan 1, 2021
26.48 M AUD
Jan 1, 2022
47.67 M AUD
Jan 1, 2023
52.66 M AUD
Jan 1, 2024
30.47 M AUD
Jan 1, 2025
28.20 M AUD
Jan 1, 2026
18.85 M AUD
The ImpediMed Current Assets history
YEARCurrent AssetsYoY
18.85 MAUD-33.15%
28.20 MAUD-7.44%
30.47 MAUD-42.15%
52.66 MAUD+10.47%
47.67 MAUD+80.04%
26.48 MAUD-6.47%
28.31 MAUD+43.61%
19.71 MAUD-51.50%
40.64 MAUD-36.33%
63.83 MAUD-29.25%
90.22 MAUD+156.79%
35.13 MAUD+175.44%
12.75 MAUD+34.70%
9.47 MAUD-45.16%
17.27 MAUD-14.56%
20.21 MAUD-4.62%
21.19 MAUD+150.04%
8.47 MAUD-21.20%
10.76 MAUD-41.31%
18.33 MAUD+1,725.41%
1.00 MAUD—
Access this data via the Eulerpool API
Get Free API Key

ImpediMed Stock analysis

What does ImpediMed do? ImpediMed Ltd is an Australian company specializing in medical devices and technologies. They were founded in 1999 and have their headquarters in Brisbane, Australia. The company is a leading provider of bioimpedance measurement devices for the diagnosis, monitoring, and treatment of lymphatic, cardiac, and other medical conditions. They have a wide range of products used in various medical fields, including oncology, lymphology, and cardiology. Their main business model is based on the development and marketing of their bioimpedance measurement devices. They also provide training and support for medical personnel to optimize the use of their devices. ImpediMed specializes in the diagnosis and treatment of lymphedema in the oncology sector, particularly using their highly precise L-Dex® device. They also analyze body composition in the cardiology sector to determine the risk of heart diseases and develop personalized treatment approaches. In recent years, ImpediMed has expanded into the European market, particularly in lymphedema diagnosis and treatment. Overall, ImpediMed Ltd is an innovative company that focuses on medical devices and technologies for the diagnosis and monitoring of cardiac and lymphatic diseases. They provide important diagnostic capabilities to medical professionals and continue to focus on growth and expansion. ImpediMed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ImpediMed stock

Current Assets of ImpediMed is 18.85 M AUD in 2026.

Current Assets of ImpediMed changed from 28.20 M AUD to 18.85 M AUD, representing a -33.15% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Assets ImpediMed since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's ImpediMed historically and in real time.

Access this data via the Eulerpool API
Get Free API Key

Balance Sheet — ImpediMed

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — ImpediMed